Celldex Therapeutics CLDX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$78.69M+3.2% | -$81.32M-21.3% | -$67.04M-18.5% | -$56.6M-5.2% | -$53.8M-14.2% | ||
| $854K+4.7% | $816K-1.0% | $824K-5.6% | $873K+0.7% | $867K+5.9% | ||
| $8.52M-4.3% | $8.91M+1.2% | $8.8M-4.2% | $9.19M-1.3% | $9.32M-4.7% | ||
| -$3K— | $0+100% | -$6K-200% | -$2K+50.0% | -$4K0.0% | ||
| -$287K-106% | $4.6M-64.8% | $13.06M+526% | $2.09M+124% | -$8.72M-209% | ||
| -$6.28M+25.8% | -$8.47M— | —— | -$1.17M+36.9% | -$1.85M— | ||
| -$1.36M— | —— | -$410K+63.4% | -$1.12M-85.4% | -$604K+28.4% | ||
| -$1.79M-193% | $1.93M— | $0+100% | -$974K-368% | $364K+339% | ||
| -$65.59M-2.6% | -$63.94M-31.5% | -$48.63M-10.5% | -$44.01M+19.1% | -$54.37M-67.4% | ||
| $1.64M+27.9% | $1.28M+191% | $440K-39.6% | $728K+175% | $265K-64.9% | ||
| $72.12M+30.1% | $55.43M-8.9% | $60.85M+22.1% | $49.85M+16.1% | $42.95M— | ||
| $327K— | —— | —— | —— | $202K— | ||
| $327K-75.8% | $1.35M+74.3% | $774K+1,129% | $63K-68.8% | $202K-47.7% | ||
| $6.86M— | —— | $12.99M— | —— | -$11.22M-39.5% | ||
| $630K-28.6% | $882K-13.4% | $1.02M-39.7% | $1.69M-25.5% | $2.27M-32.6% | ||
| -$1.79M-193% | $1.93M— | $0+100% | -$974K-368% | $364K+339% | ||
| $2.08M-48.0% | $3.99M+6,141% | $64K+106% | -$1.11M-268% | $662K-72.5% | ||
| -$6.28M+25.8% | -$8.47M— | —— | -$1.17M+36.9% | -$1.85M— | ||
| -$78.69M+3.2% | -$81.32M-21.3% | -$67.04M-18.5% | -$56.6M-5.2% | -$53.8M-14.2% | ||
| $327K-75.8% | $1.35M+74.3% | $774K+1,129% | $63K-68.8% | $202K-47.7% | ||
| $953K— | —— | $423K— | —— | $504K— | ||
| -$67.23M-3.1% | -$65.22M-32.9% | -$49.07M-9.7% | -$44.73M+18.1% | -$54.64M-64.4% | ||
| -$67.23M-3.1% | -$65.22M-32.9% | -$49.07M-9.7% | -$44.73M+18.1% | -$54.64M-64.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Celldex Therapeutics's cash flow data come from?
- Every line is extracted from Celldex Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.